Roundup Settlement Approved: How Bayer’s $7.25B Cancer Deal Pays Out
A Missouri judge approved Bayer’s Roundup settlement of up to $7.25 billion over 21 years. Who qualifies, payout tiers of $10,000 to $165,000, and what comes next.
A Missouri judge approved Bayer’s Roundup settlement of up to $7.25 billion over 21 years. Who qualifies, payout tiers of $10,000 to $165,000, and what comes next.
Novo Nordisk will cut 215 jobs at its Plainsboro, New Jersey headquarters in February 2027, taking 2026 US HQ cuts to 323 as it redesigns its sales force.
HHS and CMS awarded $47 million to 15 organisations under the MAHA ELEVATE model to test nutrition and exercise programmes for chronic disease in Original Medicare.
The European Commission has approved Revolution Medicines’ Rasonque (daraxonrasib) for previously treated metastatic pancreatic cancer, with or without a RAS mutation. Here is what the label covers and when patients may get it.
Celldex is ending barzolvolimab development in atopic dermatitis after a 131-patient Phase 2 missed its itch endpoint at both doses. The data, the biology behind the miss and what remains in the pipeline.
The FDA will miss the 22 November goal date for Savara’s inhaled molgramostim in autoimmune PAP and has set no new date. What happened, the regulatory history and what analysts expect.
Actinogen’s oral Xanamem missed its CDR-SB primary endpoint in the 247-patient XanaMIA Alzheimer’s trial. We explain the over-75 subgroup signal, the share collapse and what comes next.
Novartis, Novo, Sanofi, BMS and others say AI has cut early drug discovery time by up to half. The numbers, the frontier AI rivalry and what has not changed.
UnitedHealth sues CMS over 2027 Medicare Advantage star ratings for 45 contracts, claiming up to 1.5 stars were lost. What is at stake and what comes next.